Erik Berntorp
31 – 40 of 334
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
- Contribution to journal › Article
-
Mark
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease : Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
- Contribution to journal › Article
-
Mark
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study
- Contribution to journal › Article
-
Mark
Achieving the unimaginable : Health equity in haemophilia
- Contribution to journal › Scientific review
-
Mark
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach
- Contribution to journal › Article
- 2019
-
Mark
Cardiovascular disease-related hospitalization and mortality among persons with von Willebrand disease : A nationwide register study in Sweden
- Contribution to journal › Article
-
Mark
Direct comparison of two extended-half-life recombinant FVIII products : a randomized, crossover pharmacokinetic study in patients with severe hemophilia A
- Contribution to journal › Article
-
Mark
Evolution of replacement therapy for von Willebrand disease : From plasma fraction to recombinant von Willebrand factor
- Contribution to journal › Scientific review
-
Mark
Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis
- Contribution to journal › Scientific review
-
Mark
Moderate haemophilia in focus
- Contribution to journal › Debate/Note/Editorial
